PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2222 Views
-
Last post by NHE
-
- 0 Replies
- 1080 Views
-
Last post by NHE
-
- 0 Replies
- 11189 Views
-
Last post by NHE
-
- 0 Replies
- 2125 Views
-
Last post by Firidion
-
- 1 Replies
- 1365 Views
-
Last post by vesta
-
- 0 Replies
- 2118 Views
-
Last post by frodo
-
- 0 Replies
- 2032 Views
-
Last post by NHE
-
- 0 Replies
- 1532 Views
-
Last post by NHE
-
- 4 Replies
- 2549 Views
-
Last post by JohnC777